Last reviewed · How we verify
EDP-305
At a glance
| Generic name | EDP-305 |
|---|---|
| Sponsor | Enanta Pharmaceuticals, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH (PHASE2)
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (PHASE2)
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PHASE2)
- A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects (PHASE1)
- Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers (PHASE1)
- Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects (PHASE1)
- A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers (PHASE1)
- Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EDP-305 CI brief — competitive landscape report
- EDP-305 updates RSS · CI watch RSS
- Enanta Pharmaceuticals, Inc portfolio CI